We are live on !
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$118M
Turnover
20.7%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$118M
AUM Growth
+$17.9M
(+18%)
Cap. Flow
+$6.34M
Cap. Flow % of AUM
Cap. Flow %
5.37%
Top 10 Holdings %
Top 10 Hldgs %
16.29%
Holding
285
New
33
Increased
176
Reduced
36
Closed
26
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.28M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.28M |
| 3 |
Howard Hughes
HHH
|
+$976K |
| 4 |
IonQ
IONQ
|
+$633K |
| 5 |
The Magnum Ice Cream Company N.V.
MICC
|
+$623K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$1.41M |
| 2 |
Invesco S&P 500 Pure Value ETF
RPV
|
+$1.31M |
| 3 |
Ingram Micro Holding
INGM
|
+$913K |
| 4 |
Euronet Worldwide
EEFT
|
+$548K |
| 5 |
WSR
Whitestone REIT
WSR
|
+$460K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.59% |
| 2 | Miscellaneous | 16.64% |
| 3 | Technology | 10.39% |
| 4 | Industrials | 9.8% |
| 5 | Real Estate | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$190B
| $2.58M | 2.19% |
20,426
+166
| +0.8% | +$21.9K |
2022 Q3
15 quarters
|
|
2
Vertex Pharmaceuticals
VRTX
$127B
| $2.48M | 2.11% |
5,002
+71
| +1% | +$31.5K |
2024 Q4
6 quarters
|
|
3
Invitation Homes
INVH
$15.8B
| $2.21M | 1.87% |
73,000
| – | – |
2025 Q4
2 quarters
|
|
4
AstraZeneca
AZN
$254B
| $2.16M | 1.83% |
11,394
+162
| +1% | +$30.5K |
2024 Q4
6 quarters
|
|
5
Roivant Sciences
ROIV
$25.1B
| $1.71M | 1.45% |
48,355
+688
| +1% | +$20.3K |
2025 Q4
2 quarters
|
|
6
argenx
ARGX
$51.9B
| $1.68M | 1.42% |
1,806
+12
| +0.7% | +$9.9K |
2025 Q4
2 quarters
|
|
7
Neurocrine Biosciences
NBIX
$13.9B
| $1.64M | 1.39% |
9,727
+120
| +1% | +$17.8K |
2024 Q1
9 quarters
|
|
8
Incyte
INCY
$23B
| $1.64M | 1.39% |
14,451
+206
| +1% | +$20.4K |
2025 Q4
2 quarters
|
|
9
Axsome Therapeutics
AXSM
$8.16B
| $1.6M | 1.35% |
6,531
+93
| +1% | +$20.2K |
2025 Q4
2 quarters
|
|
10
DELISTED
Apogee Therapeutics
APGE
| $1.53M | 1.3% |
11,533
+164
| +1% | +$14.8K |
2024 Q3
7 quarters
|
|
|
11
Euronet Worldwide
EEFT
$2.43B
| $1.46M | 1.24% |
20,000
-7,855
| -28% | -$548K |
2025 Q4
2 quarters
|
|
12
Aeva Technologies
AEVA
$691M
| $1.44M | 1.22% |
50,000
| – | – |
2025 Q4
2 quarters
|
|
|
13
iShares Russell 1000 Value ETF
IWD
$83.6B
| $1.4M | 1.19% |
5,771
-6,054
| -51% | -$1.41M |
2024 Q4
6 quarters
|
|
|
14
Invesco S&P 500 Pure Value ETF
RPV
$1.67B
| $1.38M | 1.17% |
12,122
-11,760
| -49% | -$1.31M |
2024 Q4
6 quarters
|
|
|
15
Invesco QQQ Trust
QQQ
$485B
| $1.37M | 1.16% |
+1,860
| New | +$1.28M |
2026 Q2
0 quarters
|
|
|
16
Invesco NASDAQ 100 ETF
QQQM
$107B
| $1.37M | 1.16% |
+4,518
| New | +$1.28M |
2026 Q2
0 quarters
|
|
17
Saul Centers
BFS
$717M
| $1.31M | 1.11% |
35,000
| – | – |
2024 Q4
6 quarters
|
|
18
Insmed
INSM
$20.8B
| $1.25M | 1.06% |
11,699
+2,825
| +32% | +$342K |
2024 Q3
7 quarters
|
|
19
Ionis Pharmaceuticals
IONS
$7.38B
| $1.22M | 1.04% |
15,430
-4,157
| -21% | -$313K |
2024 Q4
6 quarters
|
|
20
Ascendis Pharma A/S
ASND
$15.1B
| $1.22M | 1.04% |
4,585
+59
| +1% | +$13.8K |
2025 Q4
2 quarters
|
|
21
Protagonist Therapeutics
PTGX
$8.7B
| $1.12M | 0.95% |
9,171
+131
| +1% | +$13.7K |
2023 Q3
11 quarters
|
|
22
Builders FirstSource
BLDR
$5.7B
| $1.12M | 0.95% |
12,500
+2,500
| +25% | +$200K |
2026 Q1
1 quarter
|
|
23
Unusual Machines
UMAC
$819M
| $1.12M | 0.94% |
50,000
+15,000
| +43% | +$278K |
2025 Q4
2 quarters
|
|
|
24
Howard Hughes
HHH
$3.98B
| $1.07M | 0.91% |
+15,000
| New | +$976K |
2026 Q2
0 quarters
|
|
25
iShares 1-3 Year Treasury Bond ETF
SHY
$27B
| $1.06M | 0.9% |
12,954
+3,493
| +37% | +$287K |
2023 Q1
13 quarters
|
|
Similar funds
CWM
MCM
WUW
AGAM
ERWM
KWM
KCIA
BWF
AlphaCentric Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, AlphaCentric Advisors held 285 positions worth $118M, up 18% from $100M the previous quarter. Its ten largest holdings account for 16% of the portfolio.
AlphaCentric Advisors deployed $6.34M of net new capital in Q2 2026, opening 33 new positions and adding to 176 existing holdings. Its largest new stake was Invesco NASDAQ 100 ETF: 4,518 shares worth $1.37M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 43% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $1.41M trimmed.
- AlphaCentric Advisors's largest Q2 2026 buy was Invesco NASDAQ 100 ETF: 4,518 shares worth $1.37M.
- AlphaCentric Advisors added most to Synopsys in Q2 2026, an estimated $400K increase.
- AlphaCentric Advisors's biggest Q2 2026 reduction was iShares Russell 1000 Value ETF, cutting an estimated $1.41M.
- AlphaCentric Advisors fully exited Whitestone REIT in Q2 2026, selling an estimated $460K.
- AlphaCentric Advisors's ten largest holdings make up 16% of its $118M portfolio in Q2 2026.
- AlphaCentric Advisors opened 33 new positions and closed 26 in Q2 2026.
- AlphaCentric Advisors's portfolio value rose 18% quarter-over-quarter to $118M.
Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.